- Home
- ABAT vs CTXR Comparison
ABAT vs CTXR Comparison
Compare ABAT & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABAT
- CTXR
- Stock Information
- Founded
- ABAT 2011
- CTXR 2007
- Country
- ABAT United States
- CTXR United States
- Employees
- ABAT N/A
- CTXR N/A
- Industry
- ABAT Metal Mining
- CTXR Biotechnology: Pharmaceutical Preparations
- Sector
- ABAT Basic Materials
- CTXR Health Care
- Exchange
- ABAT Nasdaq
- CTXR Nasdaq
- Market Cap
- ABAT 73.3M
- CTXR 84.9M
- IPO Year
- ABAT N/A
- CTXR N/A
- Fundamental
- Price
- ABAT $0.85
- CTXR $0.20
- Analyst Decision
- ABAT
- CTXR Strong Buy
- Analyst Count
- ABAT 0
- CTXR 2
- Target Price
- ABAT N/A
- CTXR $5.00
- AVG Volume (30 Days)
- ABAT 414.0K
- CTXR 2.0M
- Earning Date
- ABAT 11-15-2024
- CTXR 12-27-2024
- Dividend Yield
- ABAT N/A
- CTXR N/A
- EPS Growth
- ABAT N/A
- CTXR N/A
- EPS
- ABAT N/A
- CTXR N/A
- Revenue
- ABAT $545,460.00
- CTXR N/A
- Revenue This Year
- ABAT $31,748.62
- CTXR N/A
- Revenue Next Year
- ABAT N/A
- CTXR N/A
- P/E Ratio
- ABAT N/A
- CTXR N/A
- Revenue Growth
- ABAT N/A
- CTXR N/A
- 52 Week Low
- ABAT $0.75
- CTXR $0.19
- 52 Week High
- ABAT $6.45
- CTXR $1.07
- Technical
- Relative Strength Index (RSI)
- ABAT 28.88
- CTXR 29.06
- Support Level
- ABAT $0.93
- CTXR $0.31
- Resistance Level
- ABAT $1.00
- CTXR $0.51
- Average True Range (ATR)
- ABAT 0.04
- CTXR 0.06
- MACD
- ABAT -0.01
- CTXR -0.01
- Stochastic Oscillator
- ABAT 29.17
- CTXR 3.83
About ABAT American Battery Technology Company
American Battery Technology Co is engaged in lithium-ion battery recycling, battery metals and material extraction, and resource production. It is a battery metals company producing low-cost battery metals with a commitment to closed-loop, clean energy technologies.
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.